BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Equity Turnover

The Equity Turnover of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 0.49. In the previous year, Equity Turnover was 0.54 — a change of -9.38% (lower).

Equity Turnover

0.49

YoY

-9.38%

Last updated:

Equity Turnover of BrightGene Bio-Medical Technology Co is 2025 0.49 . Equity Turnover of BrightGene Bio-Medical Technology Co was 2024 0.54 . It decreases by -9.38% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
0.53 CNY
Jan 1, 2019
0.38 CNY
Jan 1, 2020
0.55 CNY
Jan 1, 2021
0.63 CNY
Jan 1, 2022
0.46 CNY
Jan 1, 2023
0.50 CNY
Jan 1, 2024
0.54 CNY
Jan 1, 2025
0.49 CNY
The BrightGene Bio-Medical Technology Co Equity Turnover history
YEAREquity TurnoverYoY
0.49-9.38%
0.54+7.55%
0.50+7.28%
0.46-25.98%
0.63+14.32%
0.55+43.15%
0.38-27.33%
0.53-25.76%
0.71-22.18%
0.91—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Equity Turnover of BrightGene Bio-Medical Technology Co is 0.49 in 2025.

Equity Turnover of BrightGene Bio-Medical Technology Co changed from 0.54 to 0.49, representing a -9.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co